* Local firms Cipla, Ranbaxy , Cadila among companies affected
MUMBAI, Sept 17 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.
country. The company and commercialization partner Ranbaxy Laboratories expect to launch the product by Q1 2015 under the brand ..... agreement, Epirus will develop and supply BOW015 and Ranbaxy will register and commercialize BOW015 in India and
Sept 15 (Reuters) - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
Indian companies are: Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories , Ltd ., Sequent Scientific Ltd., and Strides Arcolab Ltd. Under the terms of the agreements, the Indian firms
NEW DELHI/MUMBAI, Sept 15 (Reuters) - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to...
* Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy
Sept 12 (Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.
Sept 12 (Reuters) - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.
Sept 12 (Reuters) - * U.S. judges grants Pfizer Inc Ranbaxy Laboratories Ltd